HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.

Abstract
The use of bisphosphonates in children to treat low bone mineral density has increased. Safety and efficacy of pamidronate has been previously demonstrated. However, little research has been done on pamidronate infusion in the home health setting for patients with metabolic bone disease. Data were collected via a survey to assess satisfaction and convenience of infusions. Adverse events were measured by collecting calcium levels before and after infusions. Infusion costs were estimated from the standard orders from one home health agency and our infusion center. We found no difference in the rates of hypocalcemia between the two groups. The survey results showed high satisfaction for both groups, with higher scores in the home health group for convenience and stress. Home health infusions showed lower cost and less absenteeism from school and work. Home health-based pamidronate infusion appears to be safe, less expensive, and is associated with high patient satisfaction.
AuthorsEric T Rush, Kristi DeHaai, Rose M Kreikemeier, Richard E Lutz
JournalJournal of pediatric endocrinology & metabolism : JPEM (J Pediatr Endocrinol Metab) Vol. 25 Issue 5-6 Pg. 493-7 ( 2012) ISSN: 0334-018X [Print] Germany
PMID22876544 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • Pamidronate
Topics
  • Adolescent
  • Ambulatory Care (economics, standards)
  • Bone Density Conservation Agents (administration & dosage, adverse effects, economics)
  • Bone Diseases, Metabolic (drug therapy, economics)
  • Child
  • Cost-Benefit Analysis
  • Diphosphonates (administration & dosage, adverse effects, economics)
  • Health Care Surveys (economics)
  • Home Care Services (economics, standards)
  • Humans
  • Infusions, Intravenous (economics, standards)
  • Osteogenesis Imperfecta (drug therapy, economics)
  • Osteoporosis (drug therapy, economics)
  • Pamidronate
  • Patient Satisfaction
  • Program Evaluation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: